None listed
Conditions
Interventions
None listed
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria • Patients with histologically confirmed gastric cancer. • Patients who received anti-cancer treatment (e.g., surgical intervention, endoscopic resection, or systemic pharmacotherapy) following gastric cancer diagnosis. • Patients with at least one of the following data types available pre- or post-treatment: o Radiological/Endoscopic Imaging: Chest CT, abdominal CT/ultrasound, or endoscopic images. o Pathology: Histopathological slides or tissue biopsy reports. o Laboratory/Genomic Data: Blood tests or Next-Generation Sequencing (NGS) data. • Patients with linkable temporal metadata across imaging, pathology, and genomic datasets (e.g., feasibility of pre- and post-treatment RECIST(Response Evaluation Criteria in Solid Tumors) response evaluation).
Exclusion criteria
Exclusion criteria: Exclusion Criteria • Unusable imaging or pathological slide data due to poor quality (e.g., severe artifacts, low resolution). • Withdrawal of patient consent or existence of re-identification risk. • Unclear history of anti-cancer treatment or uncertain timing of therapeutic response evaluation. • Synchronous double primary cancer or severe systemic comorbidities that significantly confound gastric cancer prognosis. • Follow-up duration of less than 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive accuracy of the multimodal transformer model for chemotherapeutic response: Sensitivity, Specificity, Receiver Operating Characteristic Curve(AUROC), C-index | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive performance of the multimodal transformer model for post-treatment recurrence risk: Receiver Operating Characteristic Curve(AUROC), C-index | — |
Countries
Korea, Republic of
Contacts
Public ContactSeung Yoon Nam
Gachon University Gil Medical Center
Outcome results
None listed